The present invention relates to a novel medical use of 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB.sub.1-receptor. Said compounds are particularly suitable in the manufacture of medicaments for the treatment and/or prophylaxis of CB.sub.1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (I) 1 wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R.sub.1, R.sub.2 and R.sub.3, and the group Aa are defined as shown in the description.